Foster & Motley Inc. Has $293,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Foster & Motley Inc. lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,409 shares of the medical equipment provider’s stock after selling 473 shares during the quarter. Foster & Motley Inc.’s holdings in Zimmer Biomet were worth $293,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Schechter Investment Advisors LLC increased its position in Zimmer Biomet by 21.6% during the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock worth $476,000 after buying an additional 752 shares during the last quarter. Atria Wealth Solutions Inc. boosted its stake in shares of Zimmer Biomet by 5.9% in the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock valued at $2,312,000 after buying an additional 1,144 shares during the period. International Assets Investment Management LLC lifted its stake in Zimmer Biomet by 11,244.9% during the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after purchasing an additional 66,345 shares during the last quarter. Amalgamated Bank lifted its stake in Zimmer Biomet by 3.0% during the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after purchasing an additional 1,631 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in Zimmer Biomet by 37.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after purchasing an additional 42,539 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZBH. Truist Financial upped their target price on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Citigroup upped their target price on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Barclays upped their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $121.17 on Thursday. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $126.18 and a two-hundred day moving average price of $119.46. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25. The company has a market cap of $24.90 billion, a P/E ratio of 24.78, a PEG ratio of 2.23 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same period last year, the business posted $1.88 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.